Milestone Pharmaceuticals: Taking The Long View
Milestone Pharmaceuticals is maintaining a Hold rating after a disappointing first quarter, with revenue and earnings per share falling short of expectations. The launch of CARDAMYST, a nasal spray for PSVT, is facing challenges due to high pricing and slow uptake. Long-term prospects depend on future data for AFib-RVR, which is still years away.
- ▪Milestone Pharmaceuticals' stock is down 31% following a disappointing Q1 earnings report.
- ▪The launch of CARDAMYST is complicated by high retail pricing and competition from generics.
- ▪Despite a large potential market, the product's market penetration and value proposition remain uncertain.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911373-milestone-pharmaceuticals-stock-taking-long-view"},"author":{"@type":"Person","name":"Sean Daly","url":"https://seekingalpha.com/author/sean-daly"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
